GovChime
Notice ID: 629b88e89594dcfe6012ba25a1e8ad27Award NoticeAwarded

IMMUNOASSAY REAGENTS & INSTRUMENTATION

Awarded on June 28, 2019. Full description on SAM.gov.

Awarded tounder 959P0019C0019 (source: SAM.gov award notice)• $1.8M

Overview

Posted
June 28, 2019
Notice type
Award Notice
NAICS
325413: In-Vitro Diagnostic Substance Manufacturing
Agency
Court Services and Offender Supervision Agency

Notice details

Place of performance
WASHINGTON
PSC
66: INSTRUMENTS AND LABORATORY EQPT
Last updated
Dec 6, 2025
Award date
Jun 28, 2019
Award amount (SAM.gov award notice)
$1.8M

Identifiers

Solicitation number
959P0019Q0014
Notice ID
629b88e89594dcfe6012ba25a1e8ad27
Award number (PIID)
959P0019C0019

Description

Contract Contract 959P0019C0019 was awarded for the base year. The value of the Contract, base and option years, is $243,9000.

Full description on SAM.gov

Award Overview

Award Number

959P0019C0019

Award Amount (SAM.gov award notice)

$1.8M

Award Date

Jun 28, 2019

Awardee

Awardee UEI

GC14SNHB3JN1

Awardee CAGE Code

1K2V6

Original Solicitation

Notice ID: 629b88e89594dcfe6012ba25a1e8ad27

Posted Date: Jun 28, 2019

Original Response Deadline: Not specified

Contacts

Documents

No documents available.

Lifecycle

Solicitation:959P0019Q0014
  1. Combined Synopsis
  2. Awarded

This opportunity has been awarded.

  1. 2×
    Combined SynopsisMay 17, 2019

    IMMUNOASSAY REAGENTS & INSTRUMENTATION

    Notice db6e19d758cfafc419dc3d5aa370aa99 on SAM.gov

  2. AwardedCurrentJun 28, 2019

    IMMUNOASSAY REAGENTS & INSTRUMENTATION

    Notice 629b88e89594dcfe6012ba25a1e8ad27 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Phadia 250 Reagent and Consumables
-AwardedOpen
Combined synopsis/solicitation for Immunoassay Reagents, Supplies and Consumables to be used for patient testing on an existing Architect i1000 analyzer located at the Pathology and Laboratory Medicine Services in Southern Arizona VA Medical Center (VA Tucson).
-Combined Synopsis11/13/2026
Boise, Idaho VAMC Transfusion Services requires red blood cell reagents that meet strict quality control and compliance standards for patient testing. These reagents are essential for safely matching donated blood products to recipients who need them for life-saving treatments—a process carried out exclusively in the Transfusion Services Department. The vendor is responsible for supplying quality control check cells as well as antibody identification panel cells to fulfill these requirements and support effective patient care. 5-year agreement. Base Year Period of Performance: 12/01/2026-11/30/2027. Four option years to follow based upon the Government's needs and discretion. Transfusion Medicine supports all major hospital departments, including Emergency, Surgery, Oncology, and Medical Units. Without a dedicated Transfusion Medicine Department, these units cannot operate effectively. Each VAMC needs its own department, as services are site-specific across the VISN. The vendor must keep track of the lot numbers and expiration dates for each reagent provided to the Boise VAMC Blood Bank. Since these reagents are made from cellular material, they expire quickly. The vendor should send the new lot number shortly before the old one expires to ensure the Blood Bank always has the necessary reagents for matching blood products. The vendor shall supply the Transfusion Service with red blood cells reagents that meet the current standards and/or regulations of the Food and Drug Administration (FDA), the College of American Pathologists (CAP), the Joint Commission (TJC), and the American Association of Blood Banks (AABB) to ensure patient safety.
-Solicitation11/18/2026
Please see attached Combined Synopsis/Solicitation. See attached estimated quantities and Questions and Answers.
-Combined Synopsis11/18/2026
Requesting procurement of a high-throughput FDA approved molecular diagnostic testing system and reagents through a rental purchase agreement. Purchase order is requested to order additional specific products throughout the year necessary to perform rapid syndromic infectious disease diagnostic panels.
-Market Research11/27/2026

Additional Details

Solicitation Number

959P0019Q0014

Archive Date

Jul 13, 2019